- Home
- BDRX
as 07-11-2025 4:00pm EST
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
| Founded: | 2000 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 5.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.78 - $41.50 | Next Earning Date: | 04-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Biodexa Pharmaceuticals plc News
BDRX Breaking Stock News: Dive into BDRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
Results of Annual General Meeting
MT Newswires
17 days ago
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
GlobeNewswire
18 days ago
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
MT Newswires
20 days ago
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
GlobeNewswire
20 days ago
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
ACCESS Newswire
25 days ago
Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
GlobeNewswire
a month ago
Result of General Meeting
GlobeNewswire
a month ago
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
Compare BDRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDRX Biodexa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.